Table 2.
Assessment of primary and secondary outcome measures before (BT) and after (AT) treatment in each group
| MetS+alfuzosin (Group 1) | MetS+placebo (Group 2) | Alfuzosin (Group 3) | Placebo (Group 4) | |
|---|---|---|---|---|
| IPSS BT | 18.24±6.39 | 17.82±5.92 | 17.67±9.92 | 18.18±6.26 |
| IPSS AT | 11.53±8.35a,c,d | 16.06±6.99b | 12.50±6.36a,d | 14.18±7.89 |
| IPSS-QoL BT | 3.47±0.71 | 3.59±0.62 | 3.44±0.62 | 3.59±0.62 |
| IPSS-QoL AT | 2.65±0.79d | 3.18±0.95 | 2.72±0.83d | 3.29±0.95 |
| BPH-QoL | ||||
| BT | 16.53±11.54 | 18.88±6.72b | 12.78±6.65 | 15.71±10.91 |
| BPH-QoL AT | 9.65±12.26c,d | 16.94±7.62b | 7.06±6.37c,d | 12.18±10.82 |
| Qmax (mL/s) BT | 12.19±2.13 | 12.51±2.59b | 10.59±2.63a | 13.26±1.71 |
| Qmax (mL/s) AT | 16.25±5.48c,d | 12.12±3.32 | 13.32±3.33d | 12.96±3.24 |
| PVR (mL) BT | 54.59±26.64 | 43.71±29.24 | 43.78±30.55 | 45.88±32.76 |
| PVR (mL) AT | 57.65±35.33 | 41.18±20.80 | 47.11±30.99 | 42.76±27.97 |
Data are presented as mean±SD
a
Statistically significant difference compared to placebo group
b
Statistically significant difference compared to alfuzosine group
c
Statistically significant difference compared to MetS+placebo group
d
Statistically significant difference compared to before treatment scores; p<0.05
MetS: metabolic syndrome; IPSS: international prostate symptom score; IPSS-QoL: international prostate symptom score-quality of life; BPH-QoL: benign prostate hypertrophy-quality of life; Qmax: maximum flow rate; PVR: post-voiding residue